Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 15/20 | 0.94 |
| ▸ | P2RY6 | Q15077 | 10/20 | 0.94 |
| ▸ | P2RY4 | P51582 | 10/20 | 0.94 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21418853 | 1.00 | P2RY2 (0.94) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL21418854 | 1.00 | P2RY2 (0.94) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL17972335 | 1.00 | P2RY2 (0.94) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL14765539 | 1.00 | P2RY2 (0.94) | P2RY2P2RY6P2RY4P2RY14 | |
| Triphosphate SCHEMBL17894276 | 1.00 | P2RY2 (0.94) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL3503025 | 1.00 | P2RY2 (0.94) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL6319037 | 0.98 | P2RY2 (0.90) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL2349022 | 0.98 | P2RY2 (0.90) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL24371529 | 0.91 | P2RY2 (0.79) | P2RY2P2RY6P2RY4P2RY14 | |
| SCHEMBL21418912 | 0.91 | P2RY2 (0.79) | P2RY2P2RY6P2RY4P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122038302-A | Modified T cells and methods of making and using the same | 哈佛学院校长同事会 | 2026-05-15 | — | — | CN | claimed |
| US-12460204-B2 | Artificial nucleic acid molecules for improved protein or peptide expression | CureVac SE (DE) | 2025-11-04 | — | — | US | claimed |
| WO-2025105506-A1 | NUCLEIC ACID, DRUG COMPOSITION, AND METHOD OF PRODUCING NUCLEIC ACID | アンジェス株式会社 | 2025-05-22 | — | — | WO | claimed |
| US-20250136711-A1 | SEMENOGELIN NEUTRALIZING ANTIBODY AND EPITOPE AND APPLICATION THEREOF | SHANGHAI BIOTROY BIOTECHNIQUE CO., LTD (CN) | 2025-05-01 | — | — | US | claimed |
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | TRANSLATE BIO INC (US) | 2024-12-19 | — | — | US | claimed |
| CN-118924887-A | HPV MRNA LNP vaccine | 南京吉迈生物技术有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-20240336901-A1 | Modification of 3' Terminal Ends of Nucleic Acids by DNA Polymerase Theta | UNIV TEMPLE (US) | 2024-10-10 | — | — | US | claimed |
| US-20240327862-A1 | Methods of Treating Rheumatoid Arthritis Using RNA-Guided Genome Editing of HLA Gene | NATIONAL JEWISH HEALTH | 2024-10-03 | — | — | US | claimed |
| US-20240309447-A1 | METHODS AND KITS FOR PREPARING A SAMPLE COMPRISING ONE OR MORE RNA MOLECULES FOR SEQUENCING | THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) | 2024-09-19 | — | — | US | claimed |
| EP-4400175-A2 | METHODS OF TREATING RHEUMATOID ARTHRITIS USING RNA-GUIDED GENOME EDITING OF HLA GENE | The Regents of the University of Colorado, a body corporate (US) | 2024-07-17 | — | — | EP | claimed |
| US-20100189729-A1 | RNA-CODED ANTIBODY | CURVAC GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| US-20100047261-A1 | BASE-MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | CUREVAC GMBH (DE) | 2010-02-25 | — | — | US | claimed |
| WO-2009150156-A1 | METHOD FOR ENZYMATIC SYNTHESIS OF CHEMICALLY MODIFIED RNA | RIBOXX GMBH (DE) | 2009-12-17 | — | — | WO | claimed |
| EP-2083851-A2 | (BASE-)MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | Curevac GmbH (DE) | 2009-08-05 | — | — | EP | claimed |
| WO-2008052770-A2 | (BASE-)MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | CUREVAC GMBH (DE) | 2008-05-08 | — | — | WO | claimed |
| US-20030039976-A1 | Methods for base counting | PE CORPORATION (NY) | 2003-02-27 | — | — | US | claimed |
| JP-3331210-B2 | — | — | 2002-10-07 | — | — | JP | claimed |
| JP-2002508192-A | — | — | 2002-03-19 | — | — | JP | claimed |
| EP-1038031-A1 | MASS SPECTROMETRIC METHODS FOR SEQUENCING NUCLEIC ACIDS | SEQUENOM, INC. (US) | 2000-09-27 | — | — | EP | claimed |
| WO-1999031278-A1 | MASS SPECTROMETRIC METHODS FOR SEQUENCING NUCLEIC ACIDS | SEQUENOM, INC. (US) | 1999-06-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12460204-B2 | Artificial nucleic acid molecules for improved protein or peptide expression | RNMT, NSUN3, RNGTT | P2RY2 2992/4885P2RY6 2967/4885P2RY4 2730/4885 |
| US-20100047261-A1 | BASE-MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | RNMT, RNASE1, NSUN3 | P2RY2 4516/4885P2RY6 4642/4885P2RY4 4740/4885 |
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | NSUN3, RNMT, TRDMT1 | P2RY2 3741/4885P2RY6 3298/4885P2RY4 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.